Epizyme Announces Closing Of Public Offering Of Common Stock

CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (Nasdaq:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced the closing of its public offering of 10,557,000 shares of its common stock at a price of $15.25 per share, before underwriting discounts. The shares of common stock issued and sold in the offering at the closing include 1,377,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price less the underwriting discount.

The aggregate net proceeds before expenses to Epizyme from the offering are approximately $151.3 million, after deducting underwriting discounts and commissions.

Epizyme anticipates using the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities to fund global development costs of tazemetostat outside of Japan, including the costs of its ongoing and planned clinical trials of and regulatory activities related to tazemetostat; to initiate supply chain and market development activities and prepare for the commercial launch of tazemetostat, if approved; to fund research and development costs to identify and develop other product candidates; and for working capital and other general corporate purposes. Based on its current operating plan, Epizyme expects that the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, will enable it to fund its operating expenses and capital expenditure requirements at least into the third quarter of 2019.

Morgan Stanley, Jefferies and Leerink Partners acted as joint book-running managers for the proposed offering.

A shelf registration statement relating to the shares of common stock offered in the public offering was filed with the Securities and Exchange Commission (SEC) on April 15, 2016, and declared effective by the SEC on April 29, 2016. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A prospectus supplement related to the offering has been filed with the SEC and may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained by contacting one of the following: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Leerink Partners LLC at Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525 extension 6132 or by email at syndicate@leerink.com.

1 2 3 4
View single page >> |

Disclosure: None.

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.